Study of RP1 Monotherapy and RP1 in Combination With NivolumabResearch Question:
Is the drug RP1 alone and in combination with nivolumab safe and well tolerated in
adult subjects with advanced and/or refractory solid tumors?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly
destroy tumors and to generate an anti-tumor immune response. This is a first-in-human
clinical study to evaluate the safety and tolerability of RP1 alone and in combination
with nivolumab in adult subjects with advanced and/or refractory solid tumors.
Study Reference #: IMLT19000
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Katherine Gerich
Phone: (585) 486-0592
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search